Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) The study planned to randomly assign 300 ...
Pacific Peoples' Experiences of Cancer and Its Treatment in Aotearoa New Zealand Through Talanoa: A Qualitative Study of Samoan and Tongan Participants Acute leukemia is a group of hematologic ...
MRD status before allo-HSCT is a strong prognostic factor for OS, DFS, and CIR in AML and MDS patients. MRD-negative patients showed significantly better OS and DFS compared to MRD-positive patients, ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The major cause of disease failure in ...
John Routzahn, University of Delaware class of 2024 Applied Molecular Biology and Biotechnology (AMBB), won an NIH grant to do summer research at the National Cancer Institute in Fort Detrick as part ...
Our lab studies cell signaling and epigenetic pathways in an aggressive form of bone marrow cancer called acute myeloid leukemia (AML). Our primary focus is on a subtype of AML with mutations in FLT3, ...
Around the same time, Mack Fulwyler, an engineer working at Los Alamos National Laboratory, needed to separate particles, so he drew on existing techniques to create droplets to separate cells from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback